symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
GNPX,0.33,-0.214656,528173,19605234,0,0.32-1.94,0.0018,"Genprex, Inc.",USD,0001595248,US3724461047,372446104,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.genprex.com,"Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.",Mr. John Rodney Varner,Healthcare,US,30,877 774 4679,3300 Bee Cave Road,Austin,TX,78746,0.750194,2.09019,https://financialmodelingprep.com/image-stock/GNPX.png,2018-03-29,False,False,True,False,False
